Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q3 2016 · 10-Q
Revenue$0.00$0.00— vs Q3 2015 Net Income-$1.73M-$1.73MN/M vs Q3 2015 EPS Diluted-$0.01-$0.01— vs Q3 2015 Operating Income-$1,734,185N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
derived
ended Sep 30, 2016 · filed Oct 31, 2016 · 31 d after period end